PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.
Berger Communications Group, LLC
While translating verbal concepts and still photographs into persuasive animation that meets the clients expectations can be a difficult process, the XVIVO staff met the challenge. The client felt the animation was so well done, they came back and asked for additional still frames so their sales force could also use them in promoting the Synergy system.